Premium
Inadequate growth hormone (GH) suppression following an octreotide test dose predicts the need for adjuvant therapy to achieve ‘safe’ GH levels
Author(s) -
Aylwin Simon
Publication year - 2006
Publication title -
clinical endocrinology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.055
H-Index - 147
eISSN - 1365-2265
pISSN - 0300-0664
DOI - 10.1111/j.1365-2265.2006.02549.x
Subject(s) - acromegaly , octreotide , somatostatin , medicine , endocrinology , gastroenterology , growth hormone , hormone , nadir , adjuvant , urology , satellite , engineering , aerospace engineering